Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-226-6 | CAS number: 13701-70-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- significant methodological deficiencies
- Remarks:
- Experimental model focused on cardiovascular effects.
Data source
Reference
- Reference Type:
- publication
- Title:
- Effects of chronic administration of vanadate on blood pressure, heart rate and Na+/K+-ATPase activity in adult male Wistar rats.
- Author:
- Jadhav, A.L.; Jandhyala, B.S.
- Year:
- 1 983
- Bibliographic source:
- Arch. Int. Pharmacodyn. 263, 74-84
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Five groups of male rats received either drinking water alone, water containing 20 mg/L Na3VO4 , 1% saline , 1% saline containing 20 mg/L NA3VO4 or water containing 200 mg/L NA3VO4 for a period of 6 weeks. Average daily intake of vanadate was determined. Cardiovascular effects of chronic vanadate consumption were investigated 6 weeks after exposure by determination of systolic blood pressure and heart rate, and pressor responses to norepinephrine (NE) and angiotensin II (A-II). In addition, renal Na+/K+-ATPase activity in kidney homogenates free of V were measured.
- GLP compliance:
- not specified
- Type of method:
- in vivo
- Endpoint addressed:
- repeated dose toxicity: oral
Test material
- Reference substance name:
- Trisodium tetraoxovanadate
- EC Number:
- 237-287-9
- EC Name:
- Trisodium tetraoxovanadate
- Cas Number:
- 13721-39-6
- IUPAC Name:
- trisodium tetraoxovanadate(3-)
- Details on test material:
- - Name of test material (as cited in study report): vanadate
- Molecular formula (if other than submission substance): Na3VO4
- Substance type: technical product
No further information given.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 200 and 250 g
- Diet: standard laboratory rat chow
- Water: different drinking fluids (see below "Details on exposure")
- Acclimation period: two weeks to acclimate to the procedure of measuring systolic blood pressure
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 °C
No further information given.
Administration / exposure
- Route of administration:
- oral: drinking water
- Vehicle:
- other: water or saline soulution
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Group 1: drinking water alone
- Group 2: water containing 20 mg/L Na3VO4
- Group 3: 1% saline
- Group 4: 1% saline containing 20 mg/L NA3VO4
- Group 5: water containing 200 mg/L NA3VO4
No further information given. - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 6 weeks
- Frequency of treatment:
- continuous (in drinking water)
- Post exposure period:
- no
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
20 mg/L Na3VO4 in water (group 2)
Basis:
nominal in water
- Remarks:
- Doses / Concentrations:
200 mg NA3VO4 /L in water (group 5)
Basis:
nominal in water
- Remarks:
- Doses / Concentrations:
20 mg/L Na3VO4 in 1% saline solution (group 4)
Basis:
other: nominal in saline
- No. of animals per sex per dose:
- 8 rats per group
- Control animals:
- yes
- Details on study design:
- - Animals were randomly divided into 5 exposure groups.
- After the treatment period, the rats were anesthetized with urethane, i.p.
Examinations
- Examinations:
- - Average daily intake of vanadate was determined on the basis of fluid consumption per week.
- Cardiovascular effects of chronic vanadate consumption were investigated by weekly determination of systolic blood pressure and heart rate.
- Pressor responses to norepinephrine (NE) and angiotensin II (A-II) were determined after 6 weeks of exposure.
- In addition, renal Na+/K+-ATPase activity in kidney homogenates free of V was measured. - Positive control:
- no data
Results and discussion
- Details on results:
- - Average daily intake of vanadate: group 1: 1.9 mg/kg bw/d; group 3: 3.2 mg/kg bw/d; group 5: 22.2 mg/kg bw/d.
- Changes in arterial pressure and variations of heart rate were essentially similar in all groups during the treatment period.
- At the end of 6 weeks, studies conducted under urethane anesthesia showed that pressor responses to norepinephrine (NE) were potentiated in saline, saline + low vanadate and water + high vanadate groups when compared to that of water + low vanadate or drinking water groups.
- In all 3 groups in which NE responses were altered, renal Na+/K+-ATPase activity was significantly suppressed (25-35%).
- Pressor responses to angiotensin II (A-II) were significantly enhanced in all the groups receiving vanadate or saline when compared to that of the water group, and these changes occurred whether or not there was any change in renal Na+/K+-ATPase activity.
- Evidently, the changes noted in cardiovascular responses to vasoconstrictor agents are conducive to the development of high blood pressure.
- Failure to note sustained increase in arterial pressure during the treatment period may be due to the fact that in these rats renal compensation was not compromised.
Applicant's summary and conclusion
- Conclusions:
- In the current study, evidence was delivered that the cardiovascular system responded to vasoconstrictor agents in a dose-dependent manner after repeated oral vanadate exposure favouring the development of high blood pressure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.